Back Back
Adjuvant Olaparib in HER2- EBC

CE / CME

Germline BRCA Testing and Targeting With Adjuvant Olaparib in HER2- EBC

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit™

Nurses: 0.75 Nursing contact hour

Released: May 17, 2022

Expiration: May 16, 2023

Yara Abdou
Yara Abdou, MD
CME/CE Information

Activity

Progress
1
Course Completed
Claim Certificate

Reference

  1. Hartman AR, Kaldate RR, Sailer L, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787-2795.
  2. O'Shaughnessy JA, Johnston S, Harbeck N, et al. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer. Presented at: 2020 San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS1-01.
  3. Sharma P, Klemp JR, Kimler B, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145:707-714.
  4. Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150:71-80.
  5. Moynahan, ME, Chiu JW, Koller B, et al. BRCA1 controls homology-directed DNA repair. Molecular Cell, 1999;4:511-518.
  6. Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 2001;20:4704-4716.
  7. Ye F, He M, Huang L, et al. Insights into the impacts of BRCA mutations on clinicopathology and management of early-onset triple-negative breast cancer. Front. Oncol. 2021;10:574813.
  8. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
  9. Turk AA, Wisinski KB. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer. 2018;124:2498-2506.
  10. Rose M, Burgess JT, O'Byrne K, et al. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601.
  11. Tutt, ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405.
  12. Tutt ANJ, Garber J, Gelber RD, et al. Pre-specified event driven analysis of overall survival (OS) in the OLYMPIA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. Presented at: European Society for Medical Oncology Virtual Plenary; March 16-17, 2022. Abstract VP1-2022.
  13. Olaparib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022.
  14. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105-2122.
  15. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38:1346-1366.
  16. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.2.2022. nccn.org. Accessed May 5, 2022.
  17. National Comprehensive Cancer Network. Clinical practice guidelines in genetic/familial high-risk assessment: breast, ovarian, and pancreatic. v.2.2022. nccn.org. Accessed May 10, 2022.
  18. BRCA Gene Mutations: Cancer risk and genetic testing. cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#does-health-insurance-cover-the-cost-of-genetic-testing-for-brca1-and-brca2-variants. Accessed May 10, 2022.
  19. CDC. Genetic counseling for hereditary breast and ovarian cancer. cdc.gov/genomics/disease/breast_ovarian_cancer/counseling.htm. Accessed May 10, 2022.
  20. Moore KN, Monk BJ. Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer. Oncologist. 2016;21:954-63.
  21. LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15-e28.

BACK | NEXT
Claim Certificate